Novartis (NVS) Receives FDA Approval for Afinitor Disperz Labeling Amendment

January 26, 2015 2:17 PM

Novartis (NYSE: NVS) received FDA approval of a labeling revision for Afinitor Disperz (everolimus).In a letter to Novartis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found